We first interviewed Ben Cross five years ago, when he was the Head of Functional Genomics at Horizon Discovery, and we're delighted to welcome him back to the podcast as CTO of PhoreMost, an innovative target discovery company focused on drugging the undruggable.

Ben caught us up on what he's learned over the last five years, including why failing fast isn't a viable strategy in drug discovery, and introduced us to PhoreMost's brand new molecular glue platform, GlueSeeker.

Shane Hegarty is the Chief Scientific Officer of Axonis Therapeutics, a Boston-based Biotech targeting KCC2 to revive neurons and treat people suffering from neurological disorders.

Shane shared with us the story of his transition from academic to Biotech entrepreneur, why communication, persistence, collaboration and focus are critical skills for success, his amazing track record of securing grant funding, and much more.

Maude Tessier is the Chief Business Officer at Seismic Therapeutic, the machine learning immunology company building a discovery platform centred on parallel drug development.

Maude joined us on Careers in Discovery to talk about the impact of machine learning on drug development, taking control of her career by literally knocking on doors, balancing humility and confidence, and much more.

Vern de Biasi is VP of Business Development at BenevolentAI, one of the world's leaders in the application of cutting edge technology to drug discovery.

Vern's career has seen him travel the world, from the UK to Italy, China and the US, and he shared with us the key lessons he's learned along the way.

Jordan Lane is the Chief Scientific Officer of Ignota Labs, a company leveraging AI to rescue failed drug programmes.

Jordan joined us to talk about building conviction, seeking feedback & maintaining networks, the huge opportunity lying in failed research, and why risk is relative in your career.

Bill Eldridge is an experienced scientific and commercial leader, one of the founding team members of the VHH antibody company Isogenica, and now their CEO.

Bill joined us to talk about his career, the huge potential that still exists within antibody discovery and the magic of seeing a 96 well ELISA plate turn blue after months of failure!

Enjoy...

Namir Hassan is the CEO of Zelluna Immunotherapy, a cancer cell therapy company harnessing natural immunity to treat solid tumours.

Namir joined us on Careers in Discovery to talk about when precision medicine gets too precise, the importance of servant leadership and trusting the journey in your career.

Enjoy!

Now a Non-Executive at a range of leading Biotech companies including Spirea, PharmEnable, Macomics, NanoSyrinx and Elasmogen, Jane Dancer has built a highly successful career in Business Development in the sector.

Jane joined us to discuss that career, how she created a portfolio of NED positions, the real value of an MBA and whether you really need a PhD.

Enjoy!

"I see all the other element of my current role - the leadership, management and mentoring - as enabling the science."

Samantha Bailey-Bucktrout is the Senior Vice President of Research at Akamis Bio, a company harnessing the power of tumour gene therapy in the fight against cancer.

Samantha talked to us about her career in cancer immunotherapy, what Greek mythology has to do with modern-day Biotech, and the importance of a collaborative approach to drug development.

Enjoy!

"You can learn corporate finance. You can do Excel modelling. You can read books on negotiation. But I strongly believe that Business Development is an art, and it's something that you can only really learn by doing."

Beverley Carr is the Chief Business & Operating Officer of Amphista Therapeutics, a company re-engineering TPD therapies to tackle cancer and neurological disorders.

Beverley joined us on Careers in Discovery to talk about how Amphista are tackling the limitations of first-generation TPDs, why strategic Business Development is coming back into fashion, and the qualities that make a good BD person.

Enjoy!